ClinicalTrials.gg
CompletedNCT02003534APOTUSUpdated Jul 22, 2014Results posted

A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension

A Phase 4 interventional study of 0.15% Brimonidine Tartrate in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2014-07-22.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
376
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing brimonidine in Glaucoma, Open-Angle — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma, Open-Angle.

Enrollment
2nd of 17
376 · median 120
Started
2010
the only one that year
Phase 4
11 of 18
1 open now
Registered
13th of 18
by date
Lead sponsor
6 of 18
Allergan

Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2010, is one of 11 in phase 4, and was the 13th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 18 studies testing brimonidine in Glaucoma, Open-Angle is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing brimonidine in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of open-angle glaucoma or ocular hypertension

Exclusion criteria

Exclusion Criteria:

  • Used Alphagan® in previous 3 months
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
376 participants (actual)

Study arms

  • Experimental
    0.15% Brimonidine Tartrate

    0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

    Drug: 0.15% Brimonidine Tartrate

Interventions

  • 0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.

    Also known as: Alphagan® P

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Intraocular Pressure (IOP) in the Study Eye

    IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).

    Time frame: Baseline, Month 3

07

Results

Posted Jul 22, 2014

Participant flow

Participant flow — Overall Study
Milestone0.15% Brimonidine Tartrate
Started376
Completed329
Not completed47
Withdrew: Lost to follow-up47

Outcome measures

PrimaryChange From Baseline in Intraocular Pressure (IOP) in the Study Eye

IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).

Time frame:
Baseline, Month 3
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
Millimeters of Mercury (mmHg)0.15% Brimonidine Tartrate
Baseline25.4 ± 2.3
Change from Baseline at Month 3 (N=330)-6.3 ± 3.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.15% Brimonidine Tartrate—0/372 (0%)24/372 (6.5%)
Most frequent other events
Most frequent other events
Event0.15% Brimonidine Tartrate
Conjunctiva HyperemiaEye disorders24/372

Baseline characteristics

Age, Continuous
Age, Continuous(Years)0.15% Brimonidine Tartrate
Mean49.8 ± 17.4
Sex: Female, Male
Sex: Female, Male(Participants)0.15% Brimonidine Tartrate
Female161
Male215
08

Study locations

1 site
  • Shanghai, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2013
First posted
Dec 6, 2013
Start
Jul 2010
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Jul 22, 2014
Last update
Jul 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02003534
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Jul 2010
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Jul 22, 2014
Last update
Jul 22, 2014

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion